Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Beigene Ltd ADR (NQ: BGNE )

245.18 -11.72 (-4.56%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 6, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 273,956
Open 248.71
Bid (Size) 238.07 (1)
Ask (Size) 252.48 (1)
Prev. Close 256.90
Today's Range 242.52 - 249.98
52wk Range 118.18 - 280.62
Shares Outstanding 1,211,067,023
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Five Best And Worst Performing Healthcare Stocks In January 2023
After a sub-par performance in 2021, healthcare stocks outperformed the S&P 500 in 2022. As well, 2023 is expected to be another promising year for the sector. Let’s take a look at the five best and... 
Via Talk Markets
New Talk About It Resources Aim to Accelerate Integration of Mental Health into Quality Cancer Care
From BeiGene
Via Business Wire

Performance

YTD
+8.19%
+8.19%
1 Month
-0.31%
-0.31%
3 Month
+27.18%
+27.18%
6 Month
+21.23%
+21.23%
1 Year
+12.04%
+12.04%

More News

Read More
BeiGene to Present at Upcoming Investor Conferences
From BeiGene
Via Business Wire
4 Analysts Have This to Say About BeiGene
Via Benzinga
FDA Approves BeiGene's Brukinsa For Chronic Lymphocytic Leukemia
Via Benzinga
Zymeworks Cancer Candidate Shows Objective Response Of 41% In Bile Duct Cancer
Via Benzinga
BeiGene Earnings Perspective: Return On Capital Employed
Via Benzinga
Is Johnson & Johnson Still a Good Dividend Stock to Buy?
Via The Motley Fool
Five Best And Worst Performing Healthcare Stocks In December 2022
Via Talk Markets
Draganfly To Rally Around 87%? Here Are 10 Other Analyst Forecasts For Friday
Via Benzinga
BRUKINSA® Approved in the U.S. for Chronic Lymphocytic Leukemia
From BeiGene
Via Business Wire
What 5 Analyst Ratings Have To Say About BeiGene
Via Benzinga
Will Investors Notice Exciting Sign On BeiGene's Chart?
Via Benzinga
BRUKINSA® (zanubrutinib) Receives Marketing Authorization for Chronic Lymphocytic Leukemia (CLL) and Marginal Zone Lymphoma (MZL) in Great Britain by MHRA
From BeiGene
Via Business Wire
BeiGene Announces Expansion of Coverage on China’s National Reimbursement Drug List
From BeiGene
Via Business Wire
BeiGene Presents New Research from Tislelizumab Global Development Program at 2023 ASCO Gastrointestinal Cancers Symposium
From BeiGene
Via Business Wire
These Were The Five Best And Worst Performing Large-Cap Stocks In Q4 2022
Via Talk Markets
BeiGene to Present at the J.P. Morgan 41st Annual Healthcare Conference
From BeiGene
Via Business Wire
BeiGene Announces Acceptance of 12th Regulatory Submission in China for PD-1 Inhibitor Tislelizumab
From BeiGene
Via Business Wire
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
Via Benzinga
Week In Review: Boston Scientific Pays $523 Million For Majority Stake In Beijing Acotec Scientific
Via Talk Markets
BeiGene’s BRUKINSA® (zanubrutinib) Demonstrated Superior Progression-Free Survival Over IMBRUVICA® (ibrutinib) in Chronic Lymphocytic Leukemia in Late-Breaker at ASH
From BeiGene
Via Business Wire
PayPal To Rally Around 47%? Here Are 10 Other Price Target Changes For Monday
Via Benzinga
BeiGene Calls for Greater Integration of Mental Health in Cancer Care After New Survey Reveals Gaps/Barriers for Patients and Survivors
From BeiGene
Via Business Wire
BeiGene Stock Shows Market Leadership With Jump To 82 RS Rating
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.